2025 U.S.-Booked Air Volume: $55.3M
2025 U.S. T&E: $555M
2025 Global T&E: $950M
Primary U.S. Air Suppliers: American, Delta, United
Primary U.S. Hotel Suppliers: Hilton, Hyatt, Marriott
Primary U.S. Car Rental Suppliers: Hertz, National
Primary Global Online Booking Tool: SAP Concur
Primary Global Payment Supplier: Citi
Primary Expense Supplier: SAP Concur
Global Travel Risk Management Supplier(s): Everbridge
Consolidated Global TMC: Amex GBT
Pfizer's 2025 U.S.-booked air volume decreased nearly 18 percent compared with 2024 spend, but it is projected to increase again in 2026.
The pharmaceutical company in 2025 moved its corporate card to Citi globally from American Express and moved its travel management company to American Express Global Business Travel from BCD in more than 80 countries. It also started to use New Distribution Capability content during 2026.
Further goals for 2026 are to find ways to use AI, such as for traveler servicing, virtual agents, chatbot functionality, expense auditing and fraud detection, reporting and analytics.
Pfizer's 2025 business travel emissions were 175,000 tons of carbon dioxide equivalent, a reduction from 188,000 in 2024. The company reached its 2025 target for reducing travel-related greenhouse gas emissions, with those reported 58 percent below the 2019 baseline of 421,000 and beyond the 25 percent reduction goal for the year.
The company in November 2025 completed an up to $10 billion acquisition of obesity drug startup Metsera.
Pfizer's 2025 revenue decreased about 2 percent year over year to $62.6 billion. As of Dec. 31, 2025, the company employed approximately 75,000 individuals worldwide, down from about 80,000 a year prior.